D68.020
BillableVon Willebrand disease, type 2A
Last updated: FY2026 ICD-10-CM (Oct 1, 2025 – Sep 30, 2026) | CMS-HCC V28 (100% phase-in, PY2026)
Is D68.020 an HCC code?
Yes. D68.020 maps to Von Willebrand Disease and Other Coagulation Defects under the CMS-HCC V28 risk adjustment model (and Coagulation Defects and Other Specified Hematological Disorders under V24).
HCC Category Mapping
RAF weights shown are the community, non-dual, aged base weights from the CMS risk adjustment model file. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.
MEAT Criteria for D68.020
For D68.020 to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically — it has to be re-documented and supported each calendar year.
- MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
- EEvaluate: test results, medication response, or physical findings reviewed by the provider
- AAssess: explicit mention in the assessment or plan with acknowledgment of status
- TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis
Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed D68.020 during that encounter — not just copy-forwarded from a problem list.
What This Code Means
D68.020 is the ICD-10-CM diagnosis code for von willebrand disease, type 2a. Von Willebrand disease type 2A is a bleeding disorder where the body produces an abnormal form of a protein needed for blood clotting, resulting in prolonged bleeding from minor injuries or spontaneous bleeding. This is a moderately severe form of the condition that affects how blood platelets function. D68.020 sits in the ICD-10-CM chapter for diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism (d50-d89), within the section covering coagulation defects, purpura and other hemorrhagic conditions (d65-d69).
Under the CMS-HCC V28 risk adjustment model, D68.020 maps to Von Willebrand Disease and Other Coagulation Defects (HCC 112) with a community, non-dual, aged base RAF weight of 0.247. Under the older CMS-HCC V24 model, D68.020 maps to Coagulation Defects and Other Specified Hematological Disorders (HCC 48) with a community, non-dual, aged base RAF weight of 0.209. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.
Verify the specific type of Von Willebrand disease (type 1, 2A, 2B, 2M, 2N, or type 3) is documented in the medical record before assigning this code, as each type has a distinct ICD-10-CM code. Because D68.020 maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.
HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for D68.020 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.
Coding Tips
- •Verify the specific type of Von Willebrand disease (type 1, 2A, 2B, 2M, 2N, or type 3) is documented in the medical record before assigning this code, as each type has a distinct ICD-10-CM code
- •Look for associated bleeding manifestations (epistaxis, menorrhagia, GI bleeding) that may be coded separately if they are significant clinical concerns being managed
Clinical Significance
Von Willebrand disease type 2A is characterized by a qualitative defect in von Willebrand factor with selective loss of high-molecular-weight VWF multimers, leading to impaired platelet adhesion. Patients typically present with moderate to severe mucocutaneous bleeding. Unlike Type 1, most Type 2A patients do not respond adequately to desmopressin.
Documentation Requirements
- ✓Document VWF multimer analysis showing loss of high-molecular-weight multimers, reduced VWF activity disproportionate to VWF antigen levels, and factor VIII levels.
- ✓Record the specific genetic mutation if identified, DDAVP challenge results, and treatment plan including VWF-containing concentrates when needed.